BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Bevacizumab: trial readouts and FDA decisions
16 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 12 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Suzhou Suncadia Biopharmaceuticals Co., Ltd., AstraZeneca, AbbVie, Hoffmann-La Roche, Genelux Corporation, Mabscale, LLC, Delcath Systems Inc., Shenyang Sunshine Pharmaceutical Co., LTD.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-30 est. | P3 | Hoffmann-La Roche | NCT03148418 A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A) | Cancer | active not recruiting | 382 |
| 2026-12 est. | P3 | Genelux Corporation GNLX | NCT05281471 Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory | Platinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Cancer; Fallopian Tube Cancer; Primar | recruiting | 186 |
| 2026-12 est. | P3 | Mabscale, LLC | NCT05654454 A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | recruiting | 620 |
| 2026-12 est. | P2 | AbbVie ABBV | NCT06107413 Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Met | Unresectable Metastatic Colorectal Cancer | active not recruiting | 280 |
| 2026-12 est. | P2 | Delcath Systems Inc. DCTH | NCT06607458 Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Appr | Refractory Metastatic Colorectal Cancer | recruiting | 90 |
| 2026-12 est. | P1/P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06840002 A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer | Ovarian Cancer | recruiting | 150 |
| 2026-12 est. | P2 | Shenyang Sunshine Pharmaceutical Co., LTD. | NCT07233850 A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers | Gastric/Gastroesophageal Junction Adenocarcinoma; Metastatic Colorectal Cancer (CRC); Pancreatic Duc | not yet recruiting | 300 |
| 2026-12-01 est. | P2 | Beijing Biostar Pharmaceuticals Co., Ltd. | NCT06683703 Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases | Non-small Cell Lung Cancer Patients with Brain Metastases | not yet recruiting | 118 |
| 2026-12-24 est. | P2 | Nanjing Leads Biolabs Co.,Ltd | NCT06783647 A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)] | Advanced Solid Tumour | recruiting | 250 |
| 2026-12-30 est. | P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06465563 SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer | Biliary Tract Cancer | active not recruiting | 93 |
| 2026-12-31 est. | P1/P2 | AskGene Pharma, Inc. | NCT05867420 A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. | Advanced Solid Tumors | recruiting | 594 |
| 2026-12-31 est. | P3 | NaviFUS Corporation | NCT06496971 A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) U | Glioblastoma Multiforme; Glioblastoma; Glioblastoma Multiforme, Adult; Glioma; Brain Tumor; Brain Tu | recruiting | 32 |
| 2027-01 est. | P2/P3 | AbbVie ABBV | NCT06109272 A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as a | Hepatocellular Carcinoma | active not recruiting | 89 |
| 2027-01-13 est. | P3 | Akeso | NCT06951503 AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer | Colorectal Adenocarcinoma | recruiting | 560 |
| 2027-01-19 est. | P1/P2 | Sanofi SNY | NCT05584670 A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors | Solid Tumor | recruiting | 542 |
| 2027-02-10 est. | P2 | AstraZeneca AZN | NCT06271837 A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors | Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer) | active not recruiting | 127 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-13 est. | P1/P2 | Regeneron Pharmaceuticals REGN | NCT04626635 A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers | Advanced Solid Tumors | active not recruiting | 548 |
| 2026-10-27 est. | P2 | AstraZeneca AZN | NCT05775159 Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer | Hepatocellular Carcinoma; Biliary Tract Cancer | active not recruiting | 294 |
| 2026-10 est. | P1/P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06859775 SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer | Recurrent or Metastatic Cervical Cancer | recruiting | 100 |
| 2026-10 est. | P3 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06618664 A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular | Advanced Hepatocellular Carcinoma | recruiting | 590 |
| 2026-10 est. | P1/P2 | Biotheus Inc. | NCT06584071 A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC | HCC; Liver Cancer | not yet recruiting | 140 |
| 2026-10 est. | P1/P2 | Shanghai Hengrui Pharmaceutical Co., Ltd. | NCT06512051 A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer | Advanced or Metastatic Non-small Cell Lung Cancer | recruiting | 248 |
| 2026-10 est. | P1/P2 | Immunocore Ltd IMCR | NCT04262466 Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors | Select Advanced Solid Tumors | active not recruiting | 410 |
| 2026-09-05 est. | P1/P2 | Bristol-Myers Squibb BMY | NCT06730750 A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors | Advanced Solid Tumors | active not recruiting | 360 |
| 2026-09 est. | P2 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | NCT06558227 Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma | Hepatocellular Carcinoma | unknown | 90 |
| 2026-09 est. | P2/P3 | Bio-Thera Solutions | NCT06123884 BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer | Cervical Cancer | recruiting | 526 |
| 2026-06-30 | P2 | AstraZeneca AZN | NCT06040099 A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular | Hepatocellular Carcinoma (HCC) | active not recruiting | 58 |
| 2026-06-30 est. | P1/P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT05444088 Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma | Advanced Hepatocellular Carcinoma | unknown | 129 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.